Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 18/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682952 | 0.84 | TYMP (0.43) | TYMP | |
| Tipiracil SCHEMBL1682960 | 0.77 | TYMP (1.00) | TYMP | |
| Tipiracil SCHEMBL1682924 | 0.75 | TYMP (1.00) | TYMP | |
| SCHEMBL21071501 | 0.73 | TYMP (0.74) | TYMP | |
| Hydrochloric Acid SCHEMBL29636873 | 0.72 | TYMP (0.74) | TYMP | |
| SCHEMBL1682985 | 0.71 | TYMP (0.63) | TYMP | |
| SCHEMBL1682926 | 0.71 | TYMP (0.59) | TYMP | |
| SCHEMBL10054274 | 0.69 | TYMP (0.67) | TYMP | |
| Hydrochloric Acid SCHEMBL29636893 | 0.67 | TYMP (0.56) | TYMP | |
| SCHEMBL24709610 | 0.66 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | claimed |
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D | 2011-03-17 | — | — | US | claimed |
| US-20100240682-A1 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2204192-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2010-07-07 | — | — | EP | claimed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | claimed |
| EP-0884051-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-0763529-B1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | EP | claimed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | claimed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | claimed |
| US-5744475-A | 4-N-HET-METHYLURACIL DERIVATIVES; THYMIDINE PHOSPHORYLASE INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-28 | — | — | US | claimed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | claimed |
| WO-2018039359-A1 | METHODS FOR THE TREATMENT OF CANCER-ASSOCIATED BONE DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-01 | — | — | WO | disclosed |
| US-8440675-B2 | Potentiator of radiation therapy | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8188105-B2 | Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8188105-B2 | Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | disclosed |
| US-6159969-A | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5744475-A | 4-N-HET-METHYLURACIL DERIVATIVES; THYMIDINE PHOSPHORYLASE INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | TYMP, MTAP, NTPCR | TYMP 1/4885 |
| US-20100240682-A1 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | TYMP, MTAP, PNP | TYMP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.